# A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct07154290/  
OnCo record `nct07154290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ubamatamab and REGN7075 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07154290 by Regeneron Pharmaceuticals, with 300 participants planned, started 2026-03-18 and due to reach its primary completion in 2030-06-10. Interventions recorded: Ubamatamab, Marlotamig and Sarilumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07154290
- Phase: 2
- Setting: A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07154290: https://clinicaltrials.gov/study/NCT07154290

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [REGN7075](https://onco.cc/drugs/regn7075/), [Ubamatamab](https://onco.cc/drugs/ubamatamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct07154290.json